Delivery Order SPE2DB20D2014-SPE2DB25FD20Q
Award Date 9/29/25
Potential Completion Date 9/30/25
Potential Value $3.1K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $2,875.81 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (100 unit dose packages of 10 tablets each) on September 5, 2025, with an ultimate completion date of September 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside purchase and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a calcitonin gene-related peptide...
- The Defense Logistics Agency awarded a delivery order valued at $3,392.62 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16-count unit dose packaging) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor...
- The Defense Logistics Agency awarded a $9,639.92 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (unit dose, 10s) on September 16, 2025, with an ultimate completion date of September 17, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a calcitonin gene-related peptide receptor antagonist used for acute...
- The Defense Logistics Agency awarded a delivery order valued at $5,427.25 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packs (16 count). This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 25, 2025. UBRELVY (ubrogepant) is a calcitonin gene-related peptide receptor antagonist indicated for acute migraine treatment. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $4,164.75 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages on September 9, 2025, with completion scheduled for September 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a calcitonin gene-related peptide receptor antagonist used...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,603.68 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (100 unit-dose packs) on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a prescription medication used for acute...
- The Defense Logistics Agency awarded a delivery order valued at $16,523.11 to AmerisourceBergen Drug Corp for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging (16 count) on September 16, 2025, with completion expected by September 17, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging on July 29, 2025, with a ceiling value of $2,706.94 and ultimate completion date of July 30, 2025. UBRELVY is a calcitonin gene-related peptide (CGRP) receptor antagonist used for acute migraine treatment. This delivery order was competitively awarded without set-aside designation and carries firm fixed pricing. The contract is performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10 tablets, with a ceiling value of $1,937.86. The award, issued on September 3, 2025, represents a firm fixed price delivery order with an ultimate completion date of September 4, 2025. This contract was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $1,956.25 to AmerisourceBergen Drug Corp for UBRELVY 100 MG tablets (10 unit-dose packages) under a firm fixed-price contract. The award, issued on August 21, 2025, with an ultimate completion date of August 22, 2025, represents a non-set-aside competitive award. UBRELVY (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist used for acute migraine treatment, reflecting the Defense Logistics Agency Medical...